Supplementary Figures 1-7, Tables 1-3 from SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of <i>NCOR2/SMRT</i> That Is Associated with Tamoxifen Resistance and Control of <i>ERα</i> Transcriptional Activity

PDF file - 2.2MB, Supplementary figure 1. IC 50 shows that AK47 is more resistant than its parental cell line ZR-75-1, although response to tamoxifen treatment was still observed. Supplementary figure 2. Heat map of 11 splice variants selected for further q-PCR validation Supplementary figure 3. BQ323636.1 was over-expressed in 293T and Hela cell lines to prove its predicted molecular weight Supplementary figure 4. In ER positive patients who have received tamoxifen treatment, BQ mRNA expression level is not significantly correlated with chest wall/breast relapse. Supplementary figure 5. BQ mRNA level and BQ/WT ratio correlates with ER and PR status while BQ/WT ratio correlates with "triple-negative" status. Supplementary figure 6. Schematic representation of the functional domains of NCOR2 wild type and variant BQ323636.1 and the amino acid sequence similarity of NCOR2 among different species. Supplementary figure 7. Schematic illustration showing the postulated dominant negative inhibitory effect of splice variant BQ323636.1 on the co-repressor function of NCOR2 wild type for ER� transcriptional activity. Supplementary table 1. Brest cancer cell lines used in SpliceArray profiling, and summary of the TaqMan real time qPCR validation results. Supplementary table 2. Primer and Taqman probe sequences used in qPCR validation Supplementary table 3. The correlation between BQ mRNA level, BQ/WT ratio and various clinical pathological parameters